Inhibition of Candida albicans biofilm formation by antimycotics released from modified polydimethyl siloxane

Kristof De Prijck1, Nele De Smet, Kris Honraet

  • 1Laboratory of Pharmaceutical Microbiology, Ghent University, Harelbekestraat 72, Ghent, 9000, Belgium.

Mycopathologia
|September 24, 2009
PubMed

Insights

Antifungal medical devices are not common. Miconazole, TTO, and zinc pyrithione effectively inhibited Candida spp. biofilm formation on PDMS disks in a flow system, suggesting a contact-dependent mechanism for preventing medical device infections.

Area of Science:

  • Biomaterials Science
  • Medical Mycology
  • Infectious Diseases

Background:

  • Antifungals are underutilized in medical devices compared to disinfectants for preventing Candida spp. biofilms.
  • Candida spp. biofilm formation on medical devices like catheters and prostheses poses a significant clinical challenge.
  • Polydimethyl siloxane (PDMS) is a common material for medical devices.

Purpose of the Study:

  • To evaluate the efficacy of five antimycotics incorporated into PDMS disks for preventing Candida spp. biofilm formation.
  • To compare the performance of different incorporation methods (admixture vs. impregnation).
  • To investigate the mechanism of biofilm inhibition in different experimental setups.

Main Methods:

  • Incorporation of nystatin (admixture), trimethylsilyl-nystatin, miconazole, tea tree oil (TTO), and zinc pyrithione into PDMS disks.
  • Biofilm formation assays using microtiter plates (MTP) and a Modified Robbins Device (MRD).
  • High-Performance Liquid Chromatography (HPLC) and agar diffusion tests to assess drug release and activity.

Main Results:

  • Nystatin-medicated PDMS showed concentration-dependent biofilm inhibition in MTP but not MRD, indicating limited release.
  • Miconazole, TTO, and zinc pyrithione-impregnated PDMS disks achieved >1 log unit biofilm inhibition in the MRD.
  • Evidence suggests a contact-dependent mechanism for biofilm inhibition by miconazole, TTO, and zinc pyrithione in flow systems.

Conclusions:

  • Miconazole, TTO, and zinc pyrithione are promising candidates for antifungal medical device coatings.
  • Contact-dependent mechanisms are crucial for effective biofilm prevention in flow conditions.
  • Further research is needed to optimize antifungal incorporation for sustained efficacy in vivo.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Biofilms01:29

Biofilms

Biofilms are complex communities of microorganisms encased in a self-produced extracellular polysaccharide matrix attached to surfaces. These microbial consortia can include single or multiple species, providing enhanced survival benefits by forming organized, multilayered structures.The formation of biofilms occurs through four key stages: attachment, colonization, development, and dispersal.During attachment, free-swimming planktonic cells adhere to a surface, often facilitated by...